Brilacidin

A synthetic small-molecule mimetic of human host defense peptides (defensins). Designed to replicate the antimicrobial and immunomodulatory functions of natural defensins while offering improved stability and pharmacokinetics over native peptides.

• Mimics the amphipathic structure of human beta-defensins
• Disrupts bacterial membrane integrity via electrostatic interaction
• Inhibits bacterial lipopolysaccharide (LPS) signaling
• Modulates macrophage and dendritic cell cytokine profiles
• Resists common bacterial resistance mechanisms (efflux pumps, enzymatic degradation)

• Known hypersensitivity to defensin-mimetic compounds
• Severe hepatic impairment
• Pregnancy or breastfeeding
• Concurrent nephrotoxic agent use (monitor renal function)

Store at 2–8°C (36–46°F), protected from light. Topical formulation: stable at room temperature. IV formulation: use within 24 hours of preparation.

Developed by Innovation Pharmaceuticals (formerly Cellceutix). Completed Phase 2 clinical trials for acute bacterial skin and skin structure infections (ABSSSI) with positive results. Also studied for oral mucositis and inflammatory bowel disease. Investigated as potential COVID-19 therapeutic. Represents a novel class of non-peptide immune defense mimetics.